Navigation Links
Mount Sinai leads unprecedented, NIH-supported attempt to discover rules for assembling human tissue
Date:9/23/2009

Researchers from Mount Sinai School of Medicine and two other academic institutions have received federal funding to systematically assemble functional human kidney tissue from tissue modeled on a computer. If successful, the researchwhich ties together several emerging technologies including virtual tissue modeling and nanofabricationcould lead to a more predictable way for researchers to engineer tissue outside the body and, consequently, to screen for new drugs.

To fund the project, called Dynamics Underlying Tissue Integrity, the National Institutes of Health (NIH) awarded a five-year, $6-million grant from its Transformative Research Projects (T-R01) program. T-R01 is a new program designed to support exceptionally innovative research initiatives whose anticipated outcomes have a major impact on broad, important problems in biomedical and/or behavioral research. T-R01 awardees42 total this yearreceive part of their funding from the American Recovery and Reinvestment Act.

The leader for this multi-principal investigator project, Ravi Iyengar, PhD, Director of the Experimental Therapeutics Institute (ETI) at Mount Sinai School of Medicine, said creation of a device for assembling tissue will require his team to solve a problem that has existed since pathologists first began examining human cells under microscopes.

"Pathologists typically characterize disease in patients by studying the shape of cells and tissues, and their diagnosis has always been largely empirical," said Dr. Iyengar, who is also Dorothy H. and Lewis Rosenstiel Professor and Chair, Pharmacology and Systems Therapeutics, and Professor of Oncological Sciences and Psychiatry, Mount Sinai School of Medicine. "No one knows why cell shapes change or the rules by which tissues are organized. We want to start getting a handle on this by studying the kidney, and doing that will require the collaboration of several different disciplines."

The scientists plan to focus on the podocyte, a specialized kidney cell that sits on the organ's basement membrane and controls the filtration of small molecules from proteins. A breach in this filtration barrier is a main cause of kidney disease that often occurs among patients with diabetes, HIV, and hypertension. African-Americans with hypertension are four times more likely than whites with hypertension to develop kidney disease, a condition that currently has no cure and can eventually necessitate dialysis.

According to Dr. Iyengar, discovering the tenets underlying tissue assembly, as he and colleagues plan to do here, and having a more predictable method for assembling tissues within a nanofabricated device, would have broad clinical impact. "Lack of engineered tissue devices in vitro, or outside the cell body, is a big impediment in testing new drugs," he said. "If this experiment works and we have a methodology to assemble these tissues within nanofabricated devices, this could become a very useful screening approach for discovery of new drugs for kidney disease."

"The efforts of Dr. Iyengar's team to better understand kidney function at the cellular level will aid therapeutics research," said Dennis S. Charney, MD, the Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs at The Mount Sinai Medical Center. "Mount Sinai, whose infrastructure is designed to foster translational research, is tailor made for collaborative research projects such as this."

Much of the research will take place at the ETI, Mount Sinai's hub for developing new drugs and devices through integrating many facets of therapeutics research, and the NIGMS funded Systems Biology Center New York (SBCNY), which Dr. Iyengar also directs and which is also based at Mount Sinai. SBCNY researchers study at a systems level the molecular interactions within cells and their connection to the physiological function of tissues and organs.

"Dr. Iyengar has seized upon an extraordinary opportunitythe ability to harness systems biology to facilitate the development of new drugs and diagnostic tools," said Kenneth L. Davis, MD, President and CEO of The Mount Sinai Medical Center. "His work has the potential to create a new scientific paradigm."

The other principal investigators from Mount Sinai include John Cijiang He, MD, PhD, Associate Professor of Medicine and Nephrology and Assistant Professor of Pharmacology and Systems Therapeutics, and Susana Neves, PhD, Postdoctoral Fellow in the Department of Pharmacology and Systems Therapeutics.

Two other principal investigators sharing in the grant and lending their expertise are James C. Hone, PhD, of Columbia University, who will design and fabricate the micro- or nanometer-scale devices, and Leslie M. Loew, PhD, who pioneered the development of a computational modeling platform at the University of Connecticut Health Center called the Virtual Cell. Dr. Loew will develop computational models of how cells interact within kidney tissues.

These computational models, or virtual tissue, will form the basis for designing the device for recreating kidney function. The hope is to learn the rules of tissue organization as the team refines the device through testing the computer models and imaging the flow of cell signals within the reassembled tissue from both mouse and human cells.

Commenting on the grant, Francis S. Collins, MD, PhD, Director of the NIH, said the T-R01 program "is intended to support research that has the potential to transform the way we think about and conduct science, so the recipients represent an elite few with truly bold ideas. Competition for the awards was fierce, and standards very high."


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
2. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
3. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
4. Kaiser Permanente study: Alcohol amount, not type -- wine, beer, liquor -- triggers breast cancer
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research
7. Iron Mountain Acquires RMS Services - USA, Inc.
8. Surge in U.S. Cases of Rocky Mountain Spotted Fever
9. Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest
10. Mount Sinai recognized as Center of Excellence for Research in Alzheimers disease
11. Paramount Completes Acquisition of Chem Rx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology: